Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown in a partisan standoff over health care and spending.Pfizer Inc., one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty ...

In this articlePFEMTSRThomas Fuller | SOPA Images | Lightrocket | Getty ImagesA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer's newest bet on obesity is already showing promise. The company last week said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, that is expected to close at the end of the year. Just a week ...

Key Takeaways Novo Nordisk cut its 2025 outlook as Wegovy and Ozempic face slower uptake and rising competition.CagriSema hit key weight loss goals in late-stage studies, with a regulatory filing planned for 2026.Novo Nordisk is also advancing cagrilintide, Amycretin, and adding assets via acquisitions and licensing.Novo Nordisk (NVO) has achieved tremendous commercial success with its blockbuster semaglutide products, Wegovy (for obesity) and Ozempic (for diabetes). However, the company’s growth trajectory ...

Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as well as insured ...

It's hard to keep these longtime winners down for too long.Apple (AAPL -0.43%) and Eli Lilly (LLY 0.12%) have faced significant volatility this year. However, both companies have benefited from recent positive developments, and their shares surged over the past month or so.Here's some even better news for investors: There could be plenty of upside left for these market leaders. Apple and Eli Lilly are top picks for both growth-oriented and income-seeking investors. 1. AppleApple has faced several issues thi ...

Market leaders riding secular tailwinds are likely to be profitable long-term investments.Those who succeed at building wealth in the stock market often do so by buying and holding stakes in companies that have the ability to expand steadily over time. Such companies can frequently be found in the technology and healthcare sectors -- two sources of innovations that sometimes reshape our lives.If you have $1,000 that you don't expect to need for bills or other contingencies, and that you can commit to your p ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=169640&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

Core Viewpoint - Morgan Stanley analysts have downgraded Novo Nordisk's stock due to concerns about declining demand for its weight-loss drugs Ozempic and Wegovy, as well as doubts regarding the effectiveness of its Alzheimer's treatment [1][2][3]. Group 1: Stock Downgrade and Price Target - Morgan Stanley downgraded Novo Nordisk's rating from "equal weight" to "underweight" and reduced the price target from $59 to $47 [2][7]. - U.S.-listed shares of Novo Nordisk have decreased by a third this year, with recent trading showing a decline of less than 1% to below $55 [2][5]. Group 2: Demand and Market Concerns - Analysts noted that prescriptions for Ozempic and Wegovy have stagnated in the U.S., forecasting a decline in the U.S. GLP-1 diabetes franchise in 2026 due to market share and price pressures [4]. - The first generic competition for Ozempic outside the U.S. is expected to impact growth, particularly in Canada and emerging markets [4]. Group 3: Alzheimer's Treatment and Competitive Landscape - There are concerns that upcoming trial results for Novo Nordisk's GLP-1 treatments for Alzheimer's disease may not show statistically significant outcomes [4][5]. - Potential price cuts for Ozempic and Wegovy in Medicare Part D plans pose additional downside risks, along with doubts about the performance of Novo Nordisk's experimental obesity/diabetes combination drug CagriSemi compared to Eli Lilly's Zepbound [5].

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...